A2RL
25.7.2024 08:31:32 CEST | Business Wire | Press release
The Abu Dhabi Autonomous Racing League (A2RL), which made its impressive debut this April at the Yas Marina Circuit, has announced the next phase of its challenge with the Drone Champions League (DCL), the world's premier professional drone racing organization. Building on the success of its inaugural event, the A2RL Drone Race continues to advance the frontiers of autonomous technology, merging human skill with innovative advancements in autonomous flight.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724188405/en/
The Abu Dhabi Autonomous Racing League (A2RL) x Drone Champions League (DCL) (Graphic: AETOSWire)
The Autonomous Drone Race will bring together teams from across the globe, welcoming established drone racing teams, research institutions and enthusiastic 'rookies.' All competitors will vie for a thrilling prize purse of US$1million, as they strive to achieve maximum agility and speed while successfully maneuvering through objects in the way. Registration is now open at a2rl.io, and interested teams are invited to apply for the competition. All entries will undergo a rigorous selection process to identify the successful competing teams. Those who pass the screening will be invited to participate in a series of tasks that will allow the judging panel to assess the teams' proficiency in using an open-source simulator to fly a drone autonomously. The grand finale will be held in April 2025, where the winner will be determined.
Organized by ASPIRE, A2RL integrates artificial intelligence (AI), autonomy and extreme sports to push the boundaries of future mobility and is spotlighted as the largest autonomous racing league in the world. The A2RL extreme autonomous drone race will see competing researchers program drones to navigate through a sequence of gates, avoiding obstacles, using onboard sensors and computational power. The main goal of the race is to set a benchmark for achieving maximum innovation in algorithms while using minimal sensor technology in complex environments.
As with all grand challenges, the A2RL Drone Challenge will also include a STEM focus and high-school students will be welcome to be a part of the competition.
Announcing the new competition, H.E. Faisal Al Bannai, Secretary General of ATRC, said: “It's only when you experiment in extreme conditions that you really discover new boundaries or breakthroughs in science. We’re inspiring global collaboration, driving technological progress, and creating a future where autonomous solutions transform industries and improve lives.”
Stephane Timpano, CEO at ASPIRE, said: “This is an exciting evolution of our A2RL extreme racing series. DCL is a like-minded partner with years of invaluable drone racing experience. Together, we are not only adding a new autonomous dimension to drone racing but are also demonstrating the limitless possibilities of unmanned aerial vehicles through this competition.”
Markus Stampfer, Executive Chair of Drone Champions AG, the organizer of the Drone Champions League (DCL), said: “At DCL, our mission has always been to push the boundaries of drone racing. Having successfully merged the worlds of virtual and physical drone racing, partnering with ASPIRE to advance autonomous drone flying is a natural next step for us. We are thrilled to bring our extensive experience and expertise to this pioneering competition, supporting ASPIRE with the knowledge we've gained from years of developing race drones and working with the world's best drone pilots.”
By advancing drone technology, this race aims to make drone usage accessible for all countries, ultimately reducing costs and driving innovation across industries such as health and logistics.
For media enquiries please contact: comms@a2rl.io or ATRC@edelman.com
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724188405/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom